Ultragenyx Pharmaceutical Inc.

NasdaqGS:RARE Stock Report

Market Cap: US$3.4b

Ultragenyx Pharmaceutical Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

NasdaqGS:RARE Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
02 May 24SellUS$15,456Eric CrombezIndividual354US$43.66
18 Apr 24SellUS$6,262Eric CrombezIndividual142US$44.10
11 Mar 24SellUS$574,644Thomas KassbergIndividual11,509US$49.93
07 Mar 24SellUS$620,443Matthew FustIndividual12,195US$50.89
01 Mar 24SellUS$256,328Erik HarrisIndividual4,768US$53.76
01 Mar 24SellUS$18,332Theodore HuizengaIndividual341US$53.76
01 Mar 24SellUS$224,340John PinionIndividual4,173US$53.76
01 Mar 24SellUS$66,555Eric CrombezIndividual1,238US$53.76
01 Mar 24SellUS$54,351Thomas KassbergIndividual1,011US$53.76
01 Mar 24SellUS$201,923Karah ParschauerIndividual3,756US$53.76
07 Sep 23SellUS$6,249Theodore HuizengaIndividual163US$38.34
05 Sep 23SellUS$227,760Erik HarrisIndividual6,000US$37.96
01 Sep 23SellUS$3,326Theodore HuizengaIndividual87US$38.23
19 Jun 23SellUS$14,701Erik HarrisIndividual305US$48.20

Insider Trading Volume

Insider Buying: RARE insiders have only sold shares in the past 3 months.


Ownership Breakdown

What is the ownership structure of RARE?
Owner TypeNumber of SharesOwnership Percentage
Private Companies1,3780.0016%
State or Government35,0930.0407%
Individual Insiders2,732,4713.17%
Hedge Funds6,887,0867.98%
Institutions76,652,44988.8%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.3%.


Top Shareholders

Top 25 shareholders own 75.51% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
10.5%
The Vanguard Group, Inc.
8,700,007US$356.4m0.31%0.01%
8.29%
RTW Investments, LP
6,887,086US$282.1m27.4%4.9%
6.3%
BlackRock, Inc.
5,235,738US$214.5m-0.05%no data
5.31%
Wellington Management Group LLP
4,415,029US$180.8m-15%0.03%
4.96%
Sands Capital Management, LLC
4,118,008US$168.7m59.8%0.41%
4.15%
T. Rowe Price Group, Inc.
3,448,698US$141.3m9.13%0.01%
3.92%
State Street Global Advisors, Inc.
3,252,502US$133.2m26.7%0.01%
2.95%
Federated Hermes, Inc.
2,446,500US$100.2m11.4%0.26%
2.87%
ClearBridge Investments, LLC
2,383,492US$97.6m3.92%0.07%
2.64%
Emil Kakkis
2,190,403US$89.7m-19.9%no data
2.56%
Suvretta Capital Management, LLC
2,126,306US$87.1m213%3.76%
2.25%
Alkeon Capital Management, LLC
1,867,928US$76.5m14.9%0.58%
2.11%
Rock Springs Capital Management LP
1,754,038US$71.8m18.8%1.98%
1.9%
AllianceBernstein L.P.
1,578,603US$64.7m3.01%0.02%
1.79%
Marshall Wace LLP
1,489,486US$61.0m58.3%0.13%
1.77%
Baker Bros. Advisors LP
1,466,547US$60.1m7.32%0.73%
1.55%
Geode Capital Management, LLC
1,283,622US$52.6m18.5%no data
1.41%
Deutsche Asset & Wealth Management
1,172,866US$48.0m23.8%0.02%
1.4%
First Trust Advisors LP
1,163,077US$47.6m-3.21%0.04%
1.23%
Adage Capital Management, L.P.
1,025,000US$42.0m1,040%0.08%
1.23%
Pictet Asset Management Limited
1,023,136US$41.9m17.7%0.03%
1.2%
FMR LLC
992,951US$40.7m-3.38%no data
1.09%
BNY Mellon Asset Management
906,494US$37.1m-9.93%0.01%
1.08%
Camber Capital Management LP
900,000US$36.9m0%1.16%
1.08%
Dws Investment Gmbh
895,662US$36.7m0%0.02%
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.